axelopran

Phase 2Small molecule

axelopran is one of 27 small molecule programs targeting Head and Neck Squamous Cell Carcinoma (HNSCC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruiting

Advanced CancersNot yet recruiting

Unresectable Cutaneous MelanomaNot yet recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC)Preclinical

Not yet recruiting

Advanced CancersPhase 2

Not yet recruiting

Unresectable Cutaneous MelanomaPreclinical

Not yet recruiting

Competition

Competitive Landscape

31 competitors in Advanced Cancers

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Approved

9 2

Keytruda

Merck & Co.

Phase 2

6 3

Taxol

Teva

Phase 2

3 4

Camptosar

Pfizer

Phase 2

3 5

Adriamycin

Pfizer

Phase 2

2 6

Tecentriq

Roche

Phase 2

2 7

Abraxane

Bristol-Myers Squibb

Phase 2

2 8

Lynparza

AstraZeneca

Phase 2

1 9

Paraplatin

AAvyxa

Phase 2

3 10

Ativan

BBausch Health Americas, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalNot yet recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07662720

Phase 2Not yet recruiting

Advanced Cancers

NCT07354919

Q3 2030

PreclinicalNot yet recruiting

Unresectable Cutaneous Melanoma

NCT07631325

Clinical

Trials by Indication[1]

Advanced Cancers1 trial

Axelopran in Advanced Cancers

Not yet recruiting·HHealthPartners Institute·Phase 2·NCT07354919·34 enrolled

Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial

A Phase I/II, Open-Label, Study to Assess the Safety, Tolerability, and Efficacy of Axelopran Administered With Standard of Care Pembrolizumab in Recurrent/Metastatic HNSCC Patients Taking Opioids to Control Cancer Pain

Not yet recruiting·GGlycyx Therapeutics·Preclinical·NCT07662720·18 enrolled

Unresectable Cutaneous Melanoma1 trial

A Phase II Trial of MOR Antagonism With Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma (MORALE-MM)

Not yet recruiting·JJohn Kirkwood·Preclinical·NCT07631325·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for axelopran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — axelopran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for axelopran. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HealthPartners Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHealthPartners Institute

axelopran

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q3 2030

Trials by Indication[1]

Advanced Cancers1 trial

Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial

Unresectable Cutaneous Melanoma1 trial

References

Drug Info

Quick Facts

Related News